My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 610

    1.

    Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia.

    Meyers CD, Carr MC, Park S, Brunzell JD.

    Ann Intern Med. 2003 Dec 16;139(12):996-1002.PMID: 14678919 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products.

    Poon IO, Chow DS, Liang D.

    Am J Health Syst Pharm. 2006 Nov 1;63(21):2128-34.PMID: 17057051 [PubMed - indexed for MEDLINE]Related articles

    3.

    The prevalence of side effects with regular and sustained-release nicotinic acid.

    Gibbons LW, Gonzalez V, Gordon N, Grundy S.

    Am J Med. 1995 Oct;99(4):378-85.PMID: 7573093 [PubMed - indexed for MEDLINE]Related articles

    4.

    Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin.

    Henkin Y, Johnson KC, Segrest JP.

    JAMA. 1990 Jul 11;264(2):241-3.PMID: 2355446 [PubMed - indexed for MEDLINE]Related articles

    5.

    [Nicotinic acid: an unjustly neglected remedy]

    Zák A, Zeman M, Vecka M, Tvrzická E.

    Cas Lek Cesk. 2006;145(11):825-31. Review. Czech. PMID: 17168412 [PubMed - indexed for MEDLINE]Related articles

    6.

    Hepatotoxicity associated with sustained-release niacin.

    Dalton TA, Berry RS.

    Am J Med. 1992 Jul;93(1):102-4.PMID: 1626557 [PubMed - indexed for MEDLINE]Related articles

    7.

    Comparison of excretion of nicotinuric acid after ingestion of two controlled release nicotinic acid preparations in man.

    Figge HL, Figge J, Souney PF, Sacks FM, Shargel L, Janosik JE, Kaul AF.

    J Clin Pharmacol. 1988 Dec;28(12):1136-40.PMID: 3243933 [PubMed - indexed for MEDLINE]Related articles

    8.

    Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug.

    Carlson LA.

    Int J Clin Pract. 2004 Jul;58(7):706-13. Review.PMID: 15311728 [PubMed - indexed for MEDLINE]Related articles

    9.

    Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.

    Vega GL, Cater NB, Meguro S, Grundy SM.

    Am J Cardiol. 2005 Jun 1;95(11):1309-13.PMID: 15904634 [PubMed - indexed for MEDLINE]Related articles

    10.

    Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia.

    McCormack PL, Keating GM.

    Drugs. 2005;65(18):2719-40. Review.PMID: 16392885 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.

    Harris BN, West DS, Johnson J, Hong SH, Stowe CD.

    J Manag Care Pharm. 2004 Sep-Oct;10(5):449-55. Erratum in: J Manag Care Pharm. 2005 Jan-Feb;11(1):87. PMID: 15369428 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective.

    Roze S, Ferrières J, Bruckert E, Van Ganse E, Chapman MJ, Liens D, Renaudin C.

    Int J Clin Pract. 2007 Nov;61(11):1805-11. Epub 2007 Sep 10.PMID: 17850322 [PubMed - indexed for MEDLINE]Related articles

    13.

    Hepatitis caused by low-dose sustained-release niacin.

    Schwenk TL, Fisher M.

    J Am Board Fam Pract. 1994 May-Jun;7(3):242-4. No abstract available. PMID: 8059629 [PubMed - indexed for MEDLINE]Related articles

    14.

    Lactic acidosis associated with high-dose niacin therapy.

    Earthman TP, Odom L, Mullins CA.

    South Med J. 1991 Apr;84(4):496-7.PMID: 2014436 [PubMed - indexed for MEDLINE]Related articles

    15.

    Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.

    Rubenfire M; Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group.

    Am J Cardiol. 2004 Aug 1;94(3):306-11.PMID: 15276093 [PubMed - indexed for MEDLINE]Related articles

    16.

    Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation.

    Nirmal J, Saisivam S, Peddanna C, Muralidharan S, Godwinkumar S, Nagarajan M.

    Chem Pharm Bull (Tokyo). 2008 Oct;56(10):1455-8.PMID: 18827389 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    [Niacin in therapy]

    Nagalski A, Bryła J.

    Postepy Hig Med Dosw (Online). 2007 May 15;61:288-302. Review. Polish. PMID: 17554232 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    The bioavailability of sustained release nicotinic acid formulations.

    Neuvonen PJ, Roivas L, Laine K, Sundholm O.

    Br J Clin Pharmacol. 1991 Oct;32(4):473-6.PMID: 1958442 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.

    Menon R, Tolbert D, Cefali E.

    Biopharm Drug Dispos. 2007 Sep;28(6):297-306.PMID: 17571283 [PubMed - indexed for MEDLINE]Related articles

    20.

    [Pharmacology of niacin or nicotinic acid]

    Santos RD.

    Arq Bras Cardiol. 2005 Oct;85 Suppl 5:17-9. Epub 2006 Jan 2. Portuguese. PMID: 16400392 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity